1. P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]. (23rd June 2022) Authors: Vannucchi, A.; Mesa, R.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; McLornan, D.; Perkins, A.; Yoon, S.-S.; Gupta, V.; Kiladjian, J.-J.; Donahue, R.; Kawashima, J.; Verstovsek, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 940 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR. (23rd June 2022) Authors: Verstovsek, S.; Vannucchi, A.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; McLornan, D.; Perkins, A.; Yoon, S.-S.; Gupta, V.; Kiladjian, J.-J.; Donahue, R.; Kawashima, J.; Mesa, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗